PDS Biotechnology (PDSB) Shares Rise +31% on Clinical Milestones and Funding News
Key Takeaways
- PDSB shares climbed roughly 31% over the past 30 days, from about $0.99 on September 16, 2026, to $1.30 at the October 15, 2026 close.
- The advance followed publication of VERSATILE-002 Phase 2 data in JAMA Oncology and a Nant-led financing that helped ease funding concerns.
- Management has refocused the pipeline on PDS0301 for metastatic colorectal cancer with liver metastases, targeting a Phase 3 trial start around early 2027.
- Trading has been exceptionally volatile, with the 52-week range spanning approximately $0.20 to $1.79.
- A registration filing for the resale of up to 16.5 million shares by selling stockholders remains a potential supply overhang.
Company Background and Strategic Focus
PDS Biotechnology Corporation is a Princeton, New Jersey-based, late-stage immunotherapy company developing targeted cancer immunotherapies built on its Versamune platform. The company's lead clinical candidates are PDS0101, an HPV16-targeted T-cell immunotherapy being evaluated in combination with pembrolizumab for recurrent or metastatic head and neck cancer, and PDS0301, a tumor-targeted IL-12 immunocytokine being studied in metastatic colorectal cancer with liver metastases through a collaboration with the National Cancer Institute (NCI).
As a clinical-stage, pre-revenue biotechnology company, PDSB's valuation is driven largely by clinical data readouts, regulatory milestones, and its ability to fund ongoing development. Investors follow the stock closely for trial results, partnership activity, and financing developments, all of which can produce outsized moves in either direction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance Over 30 Days and the Quarter
Over the trailing 30 days, PDSB shares rose approximately 31%, advancing from a closing price of $0.9906 on September 16, 2026, to $1.30 at the close on October 15, 2026. The move was not linear: the stock pulled back into the $0.71–$0.75 range in late September and early October before a sharp rebound that carried it above $1.50 intraday in mid-October.
Looking further back, the trailing three-month picture is even more dramatic. After trading near $0.70 in late July, the stock fell sharply in August, dropping to roughly $0.26 in a single session on August 11, 2026. It then recovered through September and October, leaving the stock up roughly 85% from its late-July levels, albeit with extreme intraday and day-to-day swings that underscore the risk profile of a small-cap biotech navigating financing and clinical catalysts.
Key Catalysts Behind the Recent Advance
Several verified developments shaped the recent advance. In mid-September, the company announced publication of results from the VERSATILE-002 Phase 2 trial of PDS0101 in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology. The data reported a 39.3-month median overall survival in first-line, immune checkpoint inhibitor–naïve patients with HPV16-positive recurrent or metastatic head and neck cancer, alongside an objective response rate of 36% in the CPS ≥ 1 population, compared with a published 19% for pembrolizumab monotherapy.
At the same time, a Nant-led financing drew attention as a meaningful positive, with analysts noting it strengthened the company's ability to prioritize PDS0301 and reduced the funding overhang, even as limited cash and the contingent structure of part of the funding remained risks. In early October, the company hosted a key opinion leader event on PDS0301 for advanced colorectal cancer with liver metastases, where management outlined plans to advance the program toward a Phase 3 trial targeted for around the first quarter of 2027. From what I see, this strategic pivot is worth watching closely.
The sharp late-September and October price swings also coincided with a broader refocus of the company's strategy toward PDS0301, while management said it is pursuing a partnership strategy for PDS0101. Offsetting some of the enthusiasm, PDSB filed a registration statement in mid-October covering the potential resale of up to 16.5 million shares by selling stockholders, a development that can weigh on sentiment as investors assess potential future supply.
Broader Quarterly Trends and Analyst Views
The broader multi-month trend has been defined by a sharp August selloff followed by a strong recovery. The August decline reflected ongoing concerns about the company's cash position and financing needs. The subsequent rebound was powered by a sequence of clinical and strategic catalysts: publication of the VERSATILE-002 Phase 2 results in a peer-reviewed journal, the Nant-led financing that addressed near-term capital needs, and a clearer strategic pivot toward PDS0301 and its potential in metastatic colorectal cancer with liver metastases.
Analyst commentary during the period reflected this tension. H.C. Wainwright maintained a Buy rating but lowered its price target from $7 to $5, citing the Nant-led financing as a positive while flagging that financing needs remain a risk given the company's limited cash position. The combination of meaningful clinical data and ongoing balance-sheet uncertainty has kept volatility elevated throughout the quarter.
Factors to Monitor Going Forward
Looking ahead, the most important factors for PDSB include the timing and design of the planned Phase 3 trial for PDS0301 in metastatic colorectal cancer, additional data from NCI-led studies, and any partnership developments for PDS0101. Financing remains a central theme: investors will monitor the company's cash runway, the execution of the Nant-led funding, and the potential impact of the resale registration for 16.5 million shares.
Clinical readouts, regulatory interactions, and analyst revisions are likely to remain the primary short-term catalysts, while macroeconomic conditions and small-cap biotech sentiment can amplify moves in either direction. As always with clinical-stage companies, trial outcomes and capital access carry meaningful uncertainty. I’m watching this closely as the next few quarters unfold.
Using AI Tools for Biotech Analysis
In my experience, volatile names like PDSB benefit from systematic screening and pattern recognition. I have found Tickeron’s AI tools helpful for quickly comparing performance metrics across the sector and identifying potential entry or exit signals based on historical data. One tool that stands out is the AI Daily Buy/Sell Signals, which can provide an additional layer of perspective when reviewing clinical-stage stocks amid rapid price swings. These resources allow for a more structured review without replacing individual due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PDSB in upward trend: price rose above 50-day moving average on September 15, 2026
PDSB moved above its 50-day moving average on September 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on PDSB as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for PDSB just turned positive on October 05, 2026. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on September 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +15.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 190 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 76 of 105 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 44 cases where PDSB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.331) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement